Cargando…

Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment

BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung cancer (NSCLC), which is resistant to conventional chemotherapy and radiotherapy with a poor prognosis. The MET inhibitor may be effective for the patients with MET exon 14 skipping mutation. This mutation was...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Gangyi, He, Lang, Yan, Qin, Li, Yamao, Huang, Yuandong, Li, Bin, Wang, Guoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348826/
https://www.ncbi.nlm.nih.gov/pubmed/37456237
http://dx.doi.org/10.3389/fonc.2023.1167516
_version_ 1785073744919658496
author Dai, Gangyi
He, Lang
Yan, Qin
Li, Yamao
Huang, Yuandong
Li, Bin
Wang, Guoping
author_facet Dai, Gangyi
He, Lang
Yan, Qin
Li, Yamao
Huang, Yuandong
Li, Bin
Wang, Guoping
author_sort Dai, Gangyi
collection PubMed
description BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung cancer (NSCLC), which is resistant to conventional chemotherapy and radiotherapy with a poor prognosis. The MET inhibitor may be effective for the patients with MET exon 14 skipping mutation. This mutation was not detected in this patient. However, the PD-L1 TPS 60%, KRAS and TP53 mutations were detected in this patient could benefited from immunotherapy. The anlotinib is a novel multitarget antiangiogenic drug that could be effective for advanced non-small-cell lung cancer and some sarcoma patients. We report a patient with advanced pulmonary sarcomatoid carcinoma successfully treated with immunotherapy combined with antiangiogenic drugs. CASE SUMMARY: A 75-year-old male was admitted to the hospital in July 2020 because of productive cough for more than three months. The patient was diagnosed with advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis (cT4N3M1b, stage IVA) was treated in our hospital. Genetic testing revealed KRAS P.L19F mutation (abundance 19.12%) and NFEE2L2 P.E82G mutation (abundance 14.84%); TP53 P.S183 mutation (abundance 26.97%), TMB(Tumor Mutational Burden) 30.91 muts/Mb, MSS, and PD-L1 (Daco 22C3) TPS 60% were also detected. We administrated sintilimab combined with anlotinib treatment, a PD-1 inhibitor with antiangiogenic drug. The patient achieved a favorable outcome with tolerable adverse effects. CONCLUSION: Sintilimab combined with anlotinib treatment may lead to a favorable outcome for patients with advanced pulmonary sarcomatoid carcinoma.
format Online
Article
Text
id pubmed-10348826
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103488262023-07-15 Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment Dai, Gangyi He, Lang Yan, Qin Li, Yamao Huang, Yuandong Li, Bin Wang, Guoping Front Oncol Oncology BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small-cell lung cancer (NSCLC), which is resistant to conventional chemotherapy and radiotherapy with a poor prognosis. The MET inhibitor may be effective for the patients with MET exon 14 skipping mutation. This mutation was not detected in this patient. However, the PD-L1 TPS 60%, KRAS and TP53 mutations were detected in this patient could benefited from immunotherapy. The anlotinib is a novel multitarget antiangiogenic drug that could be effective for advanced non-small-cell lung cancer and some sarcoma patients. We report a patient with advanced pulmonary sarcomatoid carcinoma successfully treated with immunotherapy combined with antiangiogenic drugs. CASE SUMMARY: A 75-year-old male was admitted to the hospital in July 2020 because of productive cough for more than three months. The patient was diagnosed with advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis (cT4N3M1b, stage IVA) was treated in our hospital. Genetic testing revealed KRAS P.L19F mutation (abundance 19.12%) and NFEE2L2 P.E82G mutation (abundance 14.84%); TP53 P.S183 mutation (abundance 26.97%), TMB(Tumor Mutational Burden) 30.91 muts/Mb, MSS, and PD-L1 (Daco 22C3) TPS 60% were also detected. We administrated sintilimab combined with anlotinib treatment, a PD-1 inhibitor with antiangiogenic drug. The patient achieved a favorable outcome with tolerable adverse effects. CONCLUSION: Sintilimab combined with anlotinib treatment may lead to a favorable outcome for patients with advanced pulmonary sarcomatoid carcinoma. Frontiers Media S.A. 2023-06-30 /pmc/articles/PMC10348826/ /pubmed/37456237 http://dx.doi.org/10.3389/fonc.2023.1167516 Text en Copyright © 2023 Dai, He, Yan, Li, Huang, Li and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Dai, Gangyi
He, Lang
Yan, Qin
Li, Yamao
Huang, Yuandong
Li, Bin
Wang, Guoping
Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
title Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
title_full Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
title_fullStr Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
title_full_unstemmed Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
title_short Case Report: Advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
title_sort case report: advanced pulmonary sarcomatoid carcinoma with adrenal gland metastasis after sintilimab combined with anlotinib treatment
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348826/
https://www.ncbi.nlm.nih.gov/pubmed/37456237
http://dx.doi.org/10.3389/fonc.2023.1167516
work_keys_str_mv AT daigangyi casereportadvancedpulmonarysarcomatoidcarcinomawithadrenalglandmetastasisaftersintilimabcombinedwithanlotinibtreatment
AT helang casereportadvancedpulmonarysarcomatoidcarcinomawithadrenalglandmetastasisaftersintilimabcombinedwithanlotinibtreatment
AT yanqin casereportadvancedpulmonarysarcomatoidcarcinomawithadrenalglandmetastasisaftersintilimabcombinedwithanlotinibtreatment
AT liyamao casereportadvancedpulmonarysarcomatoidcarcinomawithadrenalglandmetastasisaftersintilimabcombinedwithanlotinibtreatment
AT huangyuandong casereportadvancedpulmonarysarcomatoidcarcinomawithadrenalglandmetastasisaftersintilimabcombinedwithanlotinibtreatment
AT libin casereportadvancedpulmonarysarcomatoidcarcinomawithadrenalglandmetastasisaftersintilimabcombinedwithanlotinibtreatment
AT wangguoping casereportadvancedpulmonarysarcomatoidcarcinomawithadrenalglandmetastasisaftersintilimabcombinedwithanlotinibtreatment